Literature DB >> 36109644

CAR Treg cells: prime suspects in therapeutic resistance.

Neeraj Saini1,2, Sattva S Neelapu3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36109644     DOI: 10.1038/s41591-022-01998-7

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   87.241


× No keyword cloud information.
  3 in total

1.  Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.

Authors:  Nicholas J Haradhvala; Mark B Leick; Katie Maurer; Satyen H Gohil; Rebecca C Larson; Ning Yao; Kathleen M E Gallagher; Katelin Katsis; Matthew J Frigault; Jackson Southard; Shuqiang Li; Michael C Kann; Harrison Silva; Max Jan; Kahn Rhrissorrakrai; Filippo Utro; Chaya Levovitz; Raquel A Jacobs; Kara Slowik; Brian P Danysh; Kenneth J Livak; Laxmi Parida; Judith Ferry; Caron Jacobson; Catherine J Wu; Gad Getz; Marcela V Maus
Journal:  Nat Med       Date:  2022-09-12       Impact factor: 87.241

2.  Advancing T cell-based cancer therapy with single-cell technologies.

Authors:  Samantha L Bucktrout; Nicholas E Banovich; Lisa H Butterfield; Cansu Cimen-Bozkus; Josephine R Giles; Zinaida Good; Daniel Goodman; Vanessa D Jonsson; Caleb Lareau; Alexander Marson; Denna M Maurer; Paul V Munson; Mike Stubbington; Sarah Taylor; Abbey Cutchin
Journal:  Nat Med       Date:  2022-09       Impact factor: 87.241

3.  Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.

Authors:  Nathalie Scholler; Regis Perbost; Frederick L Locke; Michael D Jain; Sarah Turcan; Corinne Danan; Edmund C Chang; Sattva S Neelapu; David B Miklos; Caron A Jacobson; Lazaros J Lekakis; Yi Lin; Armin Ghobadi; Jenny J Kim; Justin Chou; Vicki Plaks; Zixing Wang; Allen Xue; Mike Mattie; John M Rossi; Adrian Bot; Jérôme Galon
Journal:  Nat Med       Date:  2022-08-29       Impact factor: 87.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.